Is C4 Therapeutics, Inc. CCCC stock halal to invest in?

No, as of August 2026, C4 Therapeutics, Inc. stock (CCCC) is not currently classified as a Shariah compliant stock. This verdict follows the screening methodology of AAOIFI (the Accounting and Auditing Organization for Islamic Financial Institutions), whose Shariah Standard No. 21 is the leading global benchmark for screening halal stocks. To qualify as halal under this standard, a company must keep non-permissible income below 5% of total revenue, keep both interest-bearing investments and interest-bearing debt below 30% of market capitalisation, and have no impermissible preference share structure. C4 Therapeutics, Inc. currently does not meet the threshold for the interest-bearing investments screen. Because screenings are refreshed monthly as new financial reports are published, a non-compliant stock can regain compliant status if its financial structure changes. You can track the latest status of C4 Therapeutics, Inc. and discover Shariah compliant alternatives among the halal stocks in the Tabadulat app.

How often is C4 Therapeutics, Inc. CCCC reviewed for Shariah compliance?

Tabadulat reviews C4 Therapeutics, Inc. CCCC for Shariah compliance every month. Each review applies the AAOIFI Shariah Standard No. 21 methodology, screening the company's business activities, non-permissible income, interest-bearing investments, interest-bearing debt, and preference shares, against the company's latest available financial data. The process operates under the direct supervision of Tabadulat's dedicated Shariah Supervisory Board of Islamic finance scholars. Because compliance depends on financial ratios that move with market capitalisation and reported results, a stock's status can change from one review to the next. Monthly screening ensures the status shown for C4 Therapeutics, Inc. reflects current financial data rather than an outdated assessment, and Tabadulat app users are notified if a holding in their portfolio becomes non-compliant.

Does C4 Therapeutics, Inc. CCCC pass the AAOIFI Non Permissible Income criteria?

Yes, as of August 2026, C4 Therapeutics, Inc. stock (CCCC) passes the AAOIFI non-permissible income screen. Under AAOIFI Shariah Standard No. 21, income from impermissible sources (such as interest or riba, conventional financial services, alcohol, gambling, or tobacco) must remain below 5% of a company's total revenue. C4 Therapeutics, Inc.'s income from non-permissible sources is currently within this 5% threshold. Even permissible levels of incidental impure income should still be purified: investors donate the corresponding share of dividends to charity, as reflected in the stock's purification factor. This screen is reassessed monthly using the company's latest financial disclosures.

Does C4 Therapeutics, Inc. CCCC pass the AAOIFI Interest Bearing Investments criteria?

No, as of August 2026, C4 Therapeutics, Inc. stock (CCCC) does not pass the AAOIFI interest-bearing investments screen. Under AAOIFI Shariah Standard No. 21, the cash a company places in interest-earning instruments (such as conventional deposits, bonds, treasury bills and money-market funds) must remain below 30% of its market capitalisation. C4 Therapeutics, Inc.'s interest-bearing investments currently exceed this 30% limit, meaning too large a share of the company's value derives from riba-based instruments for the stock to qualify as halal on this criterion. The ratio moves with both the balance sheet and the share price, and is reassessed monthly.

Does C4 Therapeutics, Inc. CCCC pass the AAOIFI Interest Bearing Debt criteria?

Yes, as of August 2026, C4 Therapeutics, Inc. stock (CCCC) passes the AAOIFI interest-bearing debt screen. Under AAOIFI Shariah Standard No. 21, a company's borrowings that accrue interest (conventional bank loans, bonds and similar riba-based financing) must remain below 30% of its market capitalisation. This cap limits shareholders' exposure to interest-based leverage. C4 Therapeutics, Inc.'s interest-bearing debt is currently within the 30% threshold. Because market capitalisation changes daily, a company's debt ratio can drift toward or away from the limit even without new borrowing, which is why this screen is reassessed every month.

What is the dividend purification factor for C4 Therapeutics, Inc. CCCC stock?

C4 Therapeutics, Inc. (CCCC) is currently classified as not Shariah compliant, so no dividend purification factor applies, because purification factors are calculated only for stocks that pass the AAOIFI screens. Purification (tazkiyah) is the practice of donating to charity the small portion of dividend income that stems from incidental non-permissible sources, such as interest earned on a compliant company's cash deposits. For non-compliant stocks the issue is not purification but eligibility: under AAOIFI Shariah Standard No. 21 the stock does not currently qualify as a halal investment. If C4 Therapeutics, Inc. returns to compliance in a future monthly screening, its purification factor will be published alongside its updated status in the Tabadulat app.

Does C4 Therapeutics, Inc. CCCC pass the AAOIFI Preference Share screen?

Yes, as of August 2026, C4 Therapeutics, Inc. stock (CCCC) passes the AAOIFI preference share screen. AAOIFI Shariah Standard No. 21 prohibits investing in preference shares because they grant holders guaranteed or priority rights to dividends and capital ahead of ordinary shareholders, a structure that conflicts with the Shariah principle that investors should share profit and loss in proportion to their ownership. C4 Therapeutics, Inc. has no impermissible preference share structure affecting its ordinary shares, so the stock is compliant on this criterion. Like all AAOIFI screens, this is verified in each monthly review.

Invest Halal, Anytime, Anywhere

Download the Tabadulat app and start building your Shariah-compliant portfolio in minutes.

English

العربية

C4 Therapeutics, Inc.

NASDAQ

Shariah-Compliant

Not Shariah

CCCC

About

C4 Therapeutics, Inc.

CCCC

C4 Therapeutics Inc. is a biotechnology company focused on developing targeted protein degradation therapies to treat a variety of diseases, primarily cancer. The company's core mission is to harness their proprietary technology, known as the TORPEDO platform, to create small molecule drugs that induce the degradation of disease-causing proteins. By eliminating these proteins, C4 Therapeutics aims to offer novel treatments with improved efficacy over traditional methods. The company's innovative approach impacts the healthcare sector, particularly within oncology, as well as potential applications in neurology and other disease areas. By focusing on protein degraders instead of conventional inhibitors, C4 Therapeutics is at the forefront of a significant shift in drug discovery and development processes. With a strong pipeline of therapeutic candidates in various stages of research and development, C4 Therapeutics plays a critical role in the biopharmaceutical landscape. Headquartered in Watertown, Massachusetts, the company collaborates with leading pharmaceutical firms to leverage its platform technology, underscoring its potential to influence future medical treatments and address unmet clinical needs.

Sector:

Healthcare

Industry:

Biotechnology

Employees:

110

Website:

https://www.c4therapeutics.com

CCCC

Frequently asked questions

Related stocks

Mobile login screen for Tabadulat with fields to enter email, a Continue button, an option to create an account, and a language selector showing EN.

Step 1

Open your account.

Create your Tabadulat account in minutes: enter your details, complete identity verification, and add funds by secure transfer in multiple currencies. You're ready to start investing in halal stocks the same day.

Mobile screen showing add money interface with 100 AED amount and Manual Bank Transfer payment method selected, noting 1-2 business days processing.

Step 2

Deposit.

Add funds to your account using a secure payment method. You can deposit in multiple currencies to get started.

Step 3

Screen.

Screen Stocks for Free and explore a wide range of stocks that are ethically screened for Shariah compliance. Use our Halal Stock Screener to find the best opportunities.

C4 Therapeutics, Inc.

About

C4 Therapeutics, Inc.

CCCC

Frequently asked questions

Is C4 Therapeutics, Inc. CCCC stock halal to invest in?

How often is C4 Therapeutics, Inc. CCCC reviewed for Shariah compliance?

Does C4 Therapeutics, Inc. CCCC pass the AAOIFI Non Permissible Income criteria?

Does C4 Therapeutics, Inc. CCCC pass the AAOIFI Interest Bearing Investments criteria?

Does C4 Therapeutics, Inc. CCCC pass the AAOIFI Interest Bearing Debt criteria?

What is the dividend purification factor for C4 Therapeutics, Inc. CCCC stock?

Does C4 Therapeutics, Inc. CCCC pass the AAOIFI Preference Share screen?

Can I buy C4 Therapeutics (CCCC) stock on Tabadulat?

Open your account.

Deposit.

Screen.